nach oben

Journal of Clinical Immunology

Erschienen in:

01.08.2012

Type17 T-cells in Central Nervous System Autoimmunity and Tumors

verfasst von: Hideho Okada, Samia J. Khoury

Erschienen in: Journal of Clinical Immunology | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

Interleukin-17 (IL-17) producing Type17 T-cells, specifically T-helper (Th)17 cells reactive to central nervous system (CNS) autoantigens, manifest a higher migratory capability to the CNS parenchyma compared with other T-cell subpopulations due to their ability to penetrate the blood brain barrier (BBB). In the field of cancer immunotherapy, there are now a number of cell therapy approaches including early studies using T-cells transduced with chimeric antigen receptors in hematologic malignancy, suggesting that the use of T-cells or genetically modified T-cells could have a significant role in effective cancer therapy. However, the successful application of this strategy in solid tumors, such as CNS tumors, requires careful consideration of critical factors to improve the tumor-homing of T-cells. The current review is dedicated to discuss recent findings on the role of Type17 T-cells in CNS autoimmunity and cancer. The insight gained from these findings may lead to the development of novel therapeutic and prophylactic strategies for CNS autoimmunity and tumors.

Rosenberg SA. Cell transfer immunotherapy for metastatic solid cancer[mdash]what clinicians need to know. Nat Rev Clin Oncol. 2011;8:577–85.PubMedCrossRef

Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced Leukemia. Sci Transl Med. 2011;3:95ra73.PubMedCrossRef

Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365:725–33.PubMedCrossRef

Koon H, Atkins M. Autoimmunity and immunotherapy for cancer. N Engl J Med. 2006;354:758–60.PubMedCrossRef

Gogas H, Ioannovich J, Dafni U, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med. 2006;354:709–18.PubMedCrossRef

Peters A, Lee Y, Kuchroo VK. The many faces of Th17 cells. Curr Opin Immunol.

Jadidi-Niaragh F, Mirshafiey A. Th17 cell, the new player of neuroinflammatory process in multiple sclerosis. Scand J Immunol. 2011;74:1–13.PubMedCrossRef

El-behi M, Rostami A, Ciric B. Current views on the roles of Th1 and Th17 cells in experimental autoimmune encephalomyelitis. J Neuroimmune Pharmacol. 2010;5:189–97.PubMedCrossRef

Ando DG, Clayton J, Kono D, et al. Encephalitogenic T cells in the B10.PL model of experimental allergic encephalomyelitis (EAE) are of the Th-1 lymphokine subtype. Cell Immunol. 1989;124:132–43.PubMedCrossRef

10.

Pettinelli CB, McFarlin DE. Adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice after in vitro activation of lymph node cells by myelin basic protein: requirement for Lyt 1+ 2- T lymphocytes. J Immunol. 1981;127:1420–3.PubMed

11.

Willenborg DO, Fordham S, Bernard CC, et al. IFN-gamma plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. J Immunol. 1996;157:3223–7.PubMed

12.

Komiyama Y, Nakae S, Matsuki T, et al. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol. 2006;177:566–73.PubMed

13.

Haak S, Croxford AL, Kreymborg K, et al. IL-17A and IL-17F do not contribute vitally to autoimmune neuro-inflammation in mice. J Clin Investig. 2009;119:61–9.PubMed

14.

Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med. 2005;201:233–40.PubMedCrossRef

15.

Reboldi A, Coisne C, Baumjohann D, et al. C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat Immunol. 2009;10:514–23.PubMedCrossRef

16.

Kroenke MA, Carlson TJ, Andjelkovic AV, et al. IL-12– and IL-23–modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition. J Exp Med. 2008;205:1535–41.PubMedCrossRef

17.

Stromnes IM, Cerretti LM, Liggitt D, et al. Differential regulation of central nervous system autoimmunity by TH1 and TH17 cells. Nat Med. 2008;14:337–42.PubMedCrossRef

18.

Kebir H, Kreymborg K, Ifergan I, et al. Human TH17 lymphocytes promote blood–brain barrier disruption and central nervous system inflammation. Nat Med. 2007;13:1173–5.PubMedCrossRef

19.

Yamazaki T, Yang XO, Chung Y, et al. CCR6 regulates the migration of inflammatory and regulatory T cells. J Immunol. 2008;181:8391–401.PubMed

20.

Hirota K, Yoshitomi H, Hashimoto M, et al. Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model. J Exp Med. 2007;204:2803–12.PubMedCrossRef

21.

Kohler RE, Caon AC, Willenborg DO, et al. A role for macrophage inflammatory protein-3α/CC chemokine ligand 20 in immune priming during T cell-mediated inflammation of the central nervous system. J Immunol. 2003;170:6298–306.PubMed

22.

Liston A, Kohler RE, Townley S, et al. Inhibition of CCR6 function reduces the severity of experimental autoimmune encephalomyelitis via effects on the priming phase of the immune response. J Immunol. 2009;182:3121–30.PubMedCrossRef

23.

Hedegaard CJ, Krakauer M, Bendtzen K, et al. T helper cell type 1 (Th1), Th2 and Th17 responses to myelin basic protein and disease activity in multiple sclerosis. Immunology. 2008;125:161–9.PubMedCrossRef

24.

Tzartos JS, Friese MA, Craner MJ, et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol. 2008;172:146–55.PubMedCrossRef

25.

Brucklacher-Waldert V, Stuerner K, Kolster M, et al. Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis. Brain: J Neurol. 2009;132:3329–41.CrossRef

26.

Yang Y, Weiner J, Liu Y, et al. T-bet is essential for encephalitogenicity of both Th1 and Th17 cells. J Exp Med. 2009;206:1549–64.PubMedCrossRef

27.

Abromson-Leeman S, Bronson RT, Dorf ME. Encephalitogenic T cells that stably express both T-bet and RORγt consistently produce IFNγ but have a spectrum of IL-17 profiles. J Neuroimmunol. 2009;215:10–24.PubMedCrossRef

28.

Suryani S, Sutton I. An interferon-γ-producing Th1 subset is the major source of IL-17 in experimental autoimmune encephalitis. J Neuroimmunol. 2007;183:96–103.PubMedCrossRef

29.

Murphy ÁC, Lalor SJ, Lynch MA, et al. Infiltration of Th1 and Th17 cells and activation of microglia in the CNS during the course of experimental autoimmune encephalomyelitis. Brain Behav Immun. 2010;24:641–51.PubMedCrossRef

30.

Acosta-Rodriguez EV, Rivino L, Geginat J, et al. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol. 2007;8:639–46.PubMedCrossRef

31.

Maniati E, Soper R, Hagemann T. Up for Mischief[quest] IL-17/Th17 in the tumour microenvironment. Oncogene. 2010;29:5653–62.PubMedCrossRef

32.

Wilke CM, Kryczek I, Wei S, et al. Th17 cells in cancer: help or hindrance? Carcinogenesis. 2011;32:643–9.PubMedCrossRef

33.

Zou W, Restifo NP. TH17 cells in tumour immunity and immunotherapy. Nat Rev Immunol. 2010;10:248–56.PubMedCrossRef

34.

Kryczek I, Banerjee M, Cheng P, et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood. 2009;114:1141–9.PubMedCrossRef

35.

Murphy KM, Stockinger B. Effector T cell plasticity: flexibility in the face of changing circumstances. Nat Immunol. 2010;11:674–80.PubMedCrossRef

36.

Annunziato F, Romagnani S. The transient nature of the Th17 phenotype. Eur J Immunol. 2010;40:3312–6.PubMedCrossRef

37.

Martin-Orozco N, Chung Y, Chang SH, et al. Th17 cells promote pancreatic inflammation but only induce diabetes efficiently in lymphopenic hosts after conversion into Th1 cells. Eur J Immunol. 2009;39:216–24.PubMedCrossRef

38.

Bending D, De La Peña H, Veldhoen M, et al. Highly purified Th17 cells from BDC2.5NOD mice convert into Th1-like cells in NOD/SCID recipient mice. J Clin Investig. 2009;119:565–72.PubMedCrossRef

39.

Nistala K, Adams S, Cambrook H, et al. Th17 plasticity in human autoimmune arthritis is driven by the inflammatory environment. Proc Natl Acad Sci. 2010;107:14751–6.PubMedCrossRef

40.

Sfanos KS, Bruno TC, Maris CH, et al. Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res. 2008;14:3254–61.PubMedCrossRef

41.

Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10:942–9.PubMedCrossRef

42.

Muranski P, Boni A, Antony PA, et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood. 2008;112:362–73.PubMedCrossRef

43.

Hinrichs CS, Kaiser A, Paulos CM, et al. Type 17 CD8+ T cells display enhanced antitumor immunity. Blood. 2009;114:596–9.PubMedCrossRef

44.

Martin-Orozco N, Muranski P, Chung Y, et al. T Helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity. 2009;31:787–98.PubMedCrossRef

45.

Paulos CM, Carpenito C, Plesa G, et al. The inducible costimulator (ICOS) is critical for the development of human TH17 cells. Sci Transl Med. 2010;2:55ra78.PubMedCrossRef

46.

Garcia-Hernandez MdlL, Hamada H, Reome JB, et al. Adoptive transfer of tumor-specific Tc17 effector T cells controls the growth of B16 melanoma in mice. J Immunol. 2010;184:4215–27.CrossRef

47.

Muranski P, Borman ZA, Kerkar SP, et al. Th17 cells are long lived and retain a stem cell-like molecular signature. Immunity 2011

48.

Hamai A, Pignon P, Raimbaud I, et al. Human Th17 immune cells specific for the tumor antigen MAGE-A3 convert to IFN-γ secreting cells as they differentiate into effector T cells in vivo. Canc Res. 2012

49.

Wainwright DA, Sengupta S, Han Y, et al. The presence of IL-17A and T helper 17 cells in experimental mouse brain tumors and human glioma. PLoS One. 2010;5:e15390.PubMedCrossRef

50.

Cantini G, Pisati F, Mastropietro A, et al. A critical role for regulatory T cells in driving cytokine profiles of Th17 cells and their modulation of glioma microenvironment. Canc Immunol Immunother. 2011;60:1739–50.CrossRef

51.

Schwartzbaum JA, Huang K, Lawler S, et al. Allergy and inflammatory transcriptome is predominantly negatively correlated with CD133 expression in glioblastoma. Neuro-Oncology. 2010;12:320–7.PubMedCrossRef

52.

Hu J, Mao Y, Li M, et al. The profile of Th17 subset in glioma. Int Immunopharmacol. 2011;11:1173–9.PubMedCrossRef

53.

Zhou P, Sha H, Zhu J. The role of T-helper 17 (Th17) cells in patients with medulloblastoma. J Int Med Res. 2010;38:611–9.PubMed

Titel: Type17 T-cells in Central Nervous System Autoimmunity and Tumors
verfasst von: Hideho Okada
Samia J. Khoury
Publikationsdatum: 01.08.2012
Verlag: Springer US
Erschienen in: Journal of Clinical Immunology / Ausgabe 4/2012
Print ISSN: 0271-9142
Elektronische ISSN: 1573-2592
DOI: https://doi.org/10.1007/s10875-012-9686-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Type17 T-cells in Central Nervous System Autoimmunity and Tumors

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Denken Sie bei starker Blutung auch an die Hemmkörper-Hämophilie

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2012

Streptococcal Infections in Patients with Chronic Granulomatous Disease: Case Report and Review of the Literature

Additional Diverse Findings Expand the Clinical Presentation of DOCK8 Deficiency

Apoptotic Effects of a Chimeric Plant Virus Carrying a Mimotope of the Hepatitis C virus Hypervariable Region 1: Role of Caspases and Endoplasmic Reticulum-Stress

IDO-Competent-DCs Induced by IFN-γ Attenuate Acute Rejection in rat Liver Transplantation

B Cell Immunity in Allergic Nasal Mucosa Induces T helper 2 Cell Differentiation

Induction of IgM, IgA and IgE Antibodies in Colorectal Cancer Patients Vaccinated with a Recombinant CEA Protein

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Denken Sie bei starker Blutung auch an die Hemmkörper-Hämophilie

Update Innere Medizin